Patients suffering from potentially fatal forms of vasculitis could benefit from first ever licensed treatment, UK

MabThera (rituximab) is now licensed as the first and only treatment for two potentially life-threatening auto-immune diseases, GPA and MPA, which result in the inflammation and damage of small blood vessels and frequently involve multiple organs. The two diseases affect over 13,000 people in the UK and are characterised by the decaying inflammation of specific areas of tissue in the body that, if not treated, can lead to organ damage, organ failure and even death...
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Immune System / Vaccines Source Type: news